Gastroenterology
Intestinal immune disorders
Patient-derived EATL cells grafted mice
RCD2 patient-derived EATL cells
RCD2 patient-derived EATL cells
From patients with Celiac disease
Patient cohort
Inflammatory Bowel Disease
NCT05284136 – Exclusion Diet vs corticosteroIds in patientS With activE Crohn’s Disease (PARADISE)
NCT04777656 – Use of Crohn’s Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn’s Disease Patients.
NCT05470985 – A Study to Evaluate the Efficacy Safety and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn’s Disease With an Inadequate Response to Conventional Therapy
NCT05509777 – A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn’s Disease
NCT05092269 – A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269 – A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT04624230 – Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT05076175 – A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05784246 – A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
NCT05782907 – Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05202990 – Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis